Community-acquired pneumonia (CAP) is defined as an acute infection of the pulmonary parenchyma acquired outside the hospital and, is one of the most important causes of morbidity and mortality worldwide. According to The Global Burden of Disease Study, lower respiratory tract infections ranked 4th in terms of disability-adjusted life-years across all ages in 2019 and as a significant subset, CAP is the most frequent cause of death from infection in Europe [1,2]. Because the diagnosis is frequently made based on clinical and radiological findings and the microbial agent is not known most of the time, management of CAP can be challenging since no single antimicrobial regimen can cover all the possible causes.
